Fintel reports that on April 16, 2024, Leerink Partners initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform recommendation.
Analyst Price Forecast Suggests 107.58% Upside
As of March 31, 2024, the average one-year price target for AnaptysBio is 44.30. The forecasts range from a low of 20.20 to a high of $84.00. The average price target represents an increase of 107.58% from its latest reported closing price of 21.34.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for AnaptysBio is 17MM, an increase of 0.82%. The projected annual non-GAAP EPS is -4.21.
What is the Fund Sentiment?
There are 291 funds or institutions reporting positions in AnaptysBio. This is a decrease of 6 owner(s) or 2.02% in the last quarter. Average portfolio weight of all funds dedicated to ANAB is 0.12%, an increase of 9.29%. Total shares owned by institutions decreased in the last three months by 0.92% to 31,525K shares. 
The put/call ratio of ANAB is 0.95, indicating a bullish outlook.
What are Other Shareholders Doing?
EcoR1 Capital holds 7,521K shares representing 28.10% ownership of the company. No change in the last quarter.
Deep Track Capital holds 2,037K shares representing 7.61% ownership of the company. In it's prior filing, the firm reported owning 1,346K shares, representing an increase of 33.93%. The firm increased its portfolio allocation in ANAB by 56.19% over the last quarter.
Tang Capital Management holds 1,951K shares representing 7.29% ownership of the company. No change in the last quarter.
Boxer Capital holds 1,300K shares representing 4.86% ownership of the company. No change in the last quarter.
First Light Asset Management holds 1,237K shares representing 4.62% ownership of the company. In it's prior filing, the firm reported owning 791K shares, representing an increase of 36.08%. The firm increased its portfolio allocation in ANAB by 58.04% over the last quarter.
AnaptysBio Background Information
(This description is provided by the company.)
Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
